TRVI · Trevi Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.94M | - | $10.09M | $9.39M | $7.81M | - | $11.22M | $10.02M | $8.80M | - |
| SG&A | $4.97M | - | $3.83M | $4.33M | $3.66M | - | $2.86M | $3.27M | $3.10M | - |
| Total Operating Expenses | $14.91M | - | $13.92M | $13.72M | $11.47M | - | $14.09M | $13.29M | $11.91M | - |
| D&A | $34.0K | - | - | - | $37.0K | - | - | - | $35.0K | - |
| Operating Income | ($14.91M) | - | ($13.92M) | ($13.72M) | ($11.47M) | - | ($14.09M) | ($13.29M) | ($11.91M) | - |
| Interest Expense | - | - | $0 | $0 | $1.0K | - | $3.0K | $1.0K | $1.0K | - |
| Income Tax | ($20.0K) | - | ($15.0K) | ($21.0K) | ($11.0K) | - | ($31.0K) | ($8.0K) | ($8.0K) | - |
| Net Income | ($13.19M) | - | ($11.80M) | ($12.30M) | ($10.34M) | - | ($13.24M) | ($12.35M) | ($10.90M) | - |
| EPS - Basic | ($0.09) | - | ($0.08) | ($0.09) | ($0.09) | - | ($0.13) | ($0.12) | ($0.11) | - |
| EPS - Diluted | ($0.09) | - | ($0.08) | ($0.09) | ($0.09) | - | ($0.13) | ($0.12) | ($0.11) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.41M | $18.91M | $56.87M | $117.06M | $19.37M | $34.10M | $16.05M | $12.96M | $13.81M | $32.40M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.21M | $3.91M | $2.71M | $2.97M | $1.42M | $3.41M | $1.61M | $1.51M | $2.11M | $1.81M |
| Current Assets | $176.12M | $191.66M | $198.30M | $207.23M | $105.62M | $109.43M | $67.34M | $72.13M | $76.77M | $87.55M |
| Total Assets | $179.61M | $193.44M | $199.36M | $208.34M | $107.00M | $110.90M | $68.91M | $73.81M | $78.56M | $89.40M |
| Current Liabilities | $7.12M | $9.75M | $9.04M | $9.24M | $6.87M | $10.51M | $9.12M | $6.75M | $5.28M | $5.82M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $7.48M | $10.20M | $9.57M | $9.85M | $7.55M | $11.26M | $9.94M | $7.64M | $6.22M | $6.86M |
| Stockholders' Equity | $172.13M | $183.24M | $189.79M | $198.49M | $99.46M | $99.64M | $58.97M | $66.17M | $72.33M | $82.55M |
| Retained Earnings | ($343.00M) | ($329.80M) | ($321.49M) | ($309.69M) | ($297.38M) | ($287.05M) | ($275.63M) | ($262.39M) | ($250.04M) | ($239.13M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.69M) | - | - | - | ($13.48M) | - | - | - | ($10.47M) | - |
| Investing Cash Flow | $16.96M | - | - | - | ($9.95M) | - | - | - | ($8.09M) | - |
| Financing Cash Flow | $222.0K | - | - | - | $8.71M | - | - | - | ($28.0K) | - |
| CapEx | $102.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($16.79M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.27 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.3% | - | -5.9% | -5.9% | -9.7% | - | -19.2% | -16.7% | -13.9% | - |
| Return on equity | -7.7% | - | -6.2% | -6.2% | -10.4% | - | -22.5% | -18.7% | -15.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 24.75 | 19.66 | 21.93 | 22.42 | 15.38 | 10.41 | 7.38 | 10.68 | 14.55 | 15.03 |
| Quick ratio | 24.75 | 19.66 | 21.93 | 22.42 | 15.38 | 10.41 | 7.38 | 10.68 | 14.55 | 15.03 |
| Cash ratio | 2.73 | 1.94 | 6.29 | 12.67 | 2.82 | 3.24 | 1.76 | 1.92 | 2.62 | 5.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -11470.0x | - | -4695.7x | -13289.0x | -11906.0x | - |
| Equity multiplier | 1.04 | 1.06 | 1.05 | 1.05 | 1.08 | 1.11 | 1.17 | 1.12 | 1.09 | 1.08 |
| Liabilities / Assets | 0.04 | 0.05 | 0.05 | 0.05 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 10.1x | - | 7.0x | 3.6x | 7.4x | - | 5.7x | 4.6x | 4.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -30.0% | - | 1.2% | -3.3% | 3.7% | - | -55.7% | -58.5% | -57.4% | - |
| Net income growth (YoY) | -27.6% | - | 10.9% | 0.4% | 5.2% | - | -72.0% | -72.9% | -70.3% | - |
| EPS growth (YoY) | 0.0% | - | 38.5% | 25.0% | 18.2% | - | -62.5% | -71.4% | -83.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 73.1% | 83.9% | 221.8% | 200.0% | 37.5% | 20.7% | -34.2% | -30.4% | -28.9% | -23.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Trevi Therapeutics against the 5 most active filers in the same SIC group.